The Relation between Microvascular Complications of Type 2 Diabetic Patients and Plasma Copeptin Levels

Document Type : Original Article

Authors

1 Internal medicine department, Faculty of medicine, Beni-Suef University

2 Clinical and chemical Pathology department, Faculty of Medicine, Beni-Suef University

Abstract

Background: Diabetes mellitus (DM), commonest metabolic illness, is one of the major public health concerns worldwide. Objectives: To inspect the clinical importance of serum copeptin in patients of type 2 diabetes with and without nephropathy and to assess the relation between microvascular complication of type 2 diabetic patients and copeptin plasma levels. Patients and Methods: The study was conducted between November 2021 till May 2022, included 90 participants; 30 healthy age and sex matched control participants, 20 cases of DN with normoalbuminuria, 20 cases of DN with microalbuminuria, and 20 cases of DN with macroalbuminuria. Serum copeptin levels were measured by ELISA, Blood Urea Nitrogen (BUN), creatinine, Glycosylated Hemoglobin (HbA1c), and spot urinary albumin creatinine ratio (UACR) were done using spectrophotometry. Results: it was shown that serum copeptin level in patients with diabetic nephropathy with macro albuminuria was significantly lower than in healthy control people. There was no significant difference in level of serum copeptin in normal or abnormal fundus examination, neurological examination. Conclusion: serum copeptin level in patients with diabetic nephropathy with macroalbuminuria is significantly lower than in normal healthy control. There was no significant association was found between serum copeptin level, diabetic retinopathy nor neuropathy.

Keywords

Main Subjects

References

  1. Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: prevention and management.J Res Med Sci., 2015.
  2. Fauci AS, Kasper DLL D.L. accessmedicine.com/harrisons : principles of internal medicine, 20th edn, vol. 112, The British Journal of Psychiatry. New York: McGraw-Hill, 2018.
  3. Nam H, Cho RW. diabetesatlas.org: International Diabetes Association. IDF diabetes atlas. 9th edn, 2019.
  4. Zheng Y, Ley SH, Hu FB. https://doi.org/10.1038/nrendo.2017.151. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinal, 2017.
  5. de Boer IH, Rue TC, Hall YN. Temporal trends in the prevalence of diabetic kidney diseasein the United States.Jama, 2011.
  6. Morgenthaler NG Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker". Trends in Endocrinology and Metabolism. 2008; 19 (2): 43–9.  doi: 1016/j.tem.2007.11.001. PMID 18291667. S2CID 6008127.
  7. Velho G, Boustany RE, Lefèvre G. Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes. Diabet Care, 2016; 39: 2288–2295. https://doi.org/10.2337/dc16-1003
  8. Roussel R, Fezeu L, Marre M. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab, 2014.
  9. Meijer E, Bakker N, de Jong PE, Struck J, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int, 2010; 77(1): 29-36.
  10. Engelbertz C, Brand E, Fobker M, Fischer D, Pavenstädt H. Reinecke H Elevated copeptin is a prognostic factor for mortality even in patients with renal dysfunction. Int J Cardiol. 2016; 221: 327–32.
  11. Wen Hu, Yao-Jun Ni, Li Ma, Hai-Rong H, Liang C, Wei-Nan Y. Int J Clin Exp Med., 2015; 8(6): 9730–9736.
  12. Ahsan, Diabetic retinopathy–biomolecules and multiple pathophysiology[J]Diabetes & Metabolic Syndrome Clin. Res. Rev., 2015
  13. Zhao, Q., X. X. Wu, J. Zhou and X. Wang. Elevated plasma levels of copeptin linked to diabetic retinopathy in type 2 diabetes." Mol Cell Endocrinol, 2017; 442: 106-112.
  14. QiZ, Xiao-Xuan W, Jun Z, Xiao https://doi.org/10.1016/j.mce.2016.12.003

Files

Share

How to cite

Statistics